Oct 17, 2024 9:22 am EDT OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Oct 03, 2024 8:00 am EDT OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
Sep 13, 2024 8:09 am EDT OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
Sep 11, 2024 8:15 am EDT OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Sep 05, 2024 8:22 am EDT OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
Aug 29, 2024 7:53 am EDT OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose